The Galleri® multi-cancer early detection test detects a common signal across more than 50 types of cancer.1,2 It’s now available to eligible McGraw Hill employees and their spouses/domestic partners.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.
Early cancer detection
Detects many cancers not commonly screened for today, to allow for earlier treatment.1
Testing with ease
Completed with a simple blood draw.
Actionable results
If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy.
The Galleri test is a screening test and does not detect all cancers.
Further testing is needed to diagnose cancer if a signal is detected.
The Galleri test is available at no cost to eligible US-based McGraw Hill employees and their spouses/domestic partners who are:
Eligibility requirements
Request the test
Receive a collection kit
If the Recuro Health telemedicine physician confirms you are eligible and orders Galleri, you will receive a notification via email. Then, you can schedule a blood draw at one of GRAIL’s blood draw partners. You will receive a collection kit in the mail to take with you to your appointment.
Provide your sample
The trained technician that draws your blood sample will ship the kit to the GRAIL lab.
Receive your results
Recuro Health will reach out when your results are ready — about 2 weeks after your blood is received at the GRAIL laboratory. Your test result will be shared with you by Recuro Health.
Learn more about test results and privacy.
Galleri is a multi-cancer early detection (MCED) test that looks for a cancer signal across more than 50 types of cancer. It's a screening test, which means that while it does not diagnose cancer, it can improve your chance of finding it early.
The Galleri test is available at no cost to eligible all full U.S. employees and spouses/domestic partners enrolled on the McGraw Hill medical plan.
Those with at least one of the following elevated risk factors for cancer:
50 years or older
Use of Galleri is not recommended in individuals who are pregnant or undergoing active cancer treatment.
You can check your eligibility and request a test at galleri.com/partner/mcgrawhill.
To access the Galleri test as a covered benefit, you must request the test through this webpage.
When requesting through this website, an independent healthcare provider from Recuro Health will review your request and order the test if appropriate. The test is prescription only.
If you meet the eligibility criteria established by McGraw Hill in partnership with GRAIL (see "Who is eligible" question above), the full cost of the Galleri test is covered. The cost of the blood draw is also included if you visit a GRAIL partner lab.
The Galleri test is provided at no cost to eligible employees or dependents only when obtained through this authorized site galleri.com/partner/mcgrawhill.
The blood draw associated with Galleri must occur on a date you are covered under this employee benefit. Employees are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after McGraw Hill benefit coverage has ended.
You will need to enter your McGraw Hill Medical ID.
Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Additionally, those who do not meet the eligibility criteria as stated by McGraw Hill will not be covered by the benefit
GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. GRAIL is the company that manufactures the Galleri multi-cancer early detection test. You may receive information or communications from GRAIL or Galleri about your benefit or the Galleri test.
Recuro Health is an independent telemedicine, nationwide care provider and a GRAIL partner, supporting virtual physician consultations related to receiving the Galleri test. A Recuro Health physician will review your test request and order the test, if appropriate. A Recuro Health provider will also share your test result with you.
Under the McGraw Hill benefit program employees and eligible dependents for the Galleri test will be able to complete the Galleri test every 365 days.
To access the Galleri test as a covered benefit, you must request the test through this web page. An independent physician from Recuro Health will review your request and order the test, if appropriate.
The Galleri test is provided at no cost to eligible employees or dependents only when obtained through this authorized site https://www.Galleri.com/McGrawHill.
When you request the test, you are given the option to enter your primary healthcare provider's contact information so your test result is automatically shared if a cancer signal is detected. If no cancer signal is detected, you can share the result with your provider, but we will not automatically send it.
The blood draw associated with Galleri must occur on a date you are covered under this employee benefit. Employees are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after McGraw Hill benefit coverage has ended.
The Galleri test is currently available at no cost to eligible US-based McGraw Hill employees and their covered dependents enrolled in a US McGraw Hill health plan(Aetna, UHC) and that also meet the eligibility criteria established by McGraw Hill in partnership with GRAIL (see "Who is eligible for the test" question above).
If you are not eligible for this benefit but would still like to learn more about the test, visit Galleri.com. Those not eligible would be responsible for the cost of the test and Recuro Health provider services.
Other family members or friends not eligible through the McGraw Hill benefit may learn more about the test on Galleri.com. Those not eligible would be responsible for the cost of the test and Recuro Health provider services.
Note: Only the member requesting a Galleri test kit can take the test.
If eligible through the McGraw Hill benefit you will not need to pay for the test using your flexible spending account (FSA) or health savings account (HSA).
However, if you know someone interested in the Galleri test that is not eligible through McGraw Hill, they may be able to use pre-tax dollars in a flexible spending account (FSA) or health savings account (HSA) to pay for the Galleri test. Check with the FSA/HSA account administrator or insurance company to determine eligibility.
Your employer only receives de-identified and aggregated information across all employees (e.g. how many tests have been requested) and will not receive individual results.
The Recuro Health provider that orders the test will receive your test result and share it with you. Your test result and medical information are confidential and access is limited to individuals who need the information for a specific purpose.
For example: If a cancer signal is detected, your test result will be shared with your primary healthcare provider (if you gave their contact information) so they can guide your next steps
Your individual test results will not be shared with McGraw Hill.
If you receive a “Cancer Signal Detected” result from the Galleri test, and follow-up diagnostic testing confirms a cancer diagnosis, it will not impact your premiums through McGraw Hill.
If you receive a “Cancer Signal Detected” result from the Galleri test, and follow-up diagnostic testing confirms a cancer diagnosis, it will not impact your other insurance products, like life insurance, through McGraw Hill.
Existing cancer or cancer that is in remission would need to be disclosed in most insurance applications. This does not necessarily mean that new policy applications would be declined or require higher premiums.
The Galleri test is a screening test for asymptomatic adults with an elevated risk for cancer, such as those aged 50 or older. Galleri detects a signal shared by multiple cancers; when a Cancer Signal is Detected, Galleri predicts Cancer Signal Origin to guide diagnostic evaluation.
The Galleri test looks for active cancer and does not predict future genetic risk for cancer.
All cells in your body, including cancer cells, release DNA fragments into the bloodstream. These fragments are called cell-free DNA. The Galleri test screens your blood sample for cell-free DNA and identifies whether it comes from healthy or cancer cells. Cell-free DNA from cancer cells also contains information about the organ or tissue of origin. The process uses advanced technology and pattern recognition to detect a Cancer Signal and predict the Cancer Signal Origin. This information helps guide healthcare providers to perform a diagnostic evaluation for cancer.
Cancer risk increases for everyone as they age, regardless of family history—only 5% to 10% of cancers are inherited.
Age is the biggest risk factor for cancer. In fact, adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.
Galleri detects a signal shared by multiple cancers, in a clinical study, Galleri detected a signal shared by over 50 types of cancer —including some fast-spreading and deadly cancers responsible for approximately two-thirds of cancer deaths.The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Most people who take the Galleri test will receive a “No Cancer Signal Detected” result. A “Cancer Signal Detected” result is expected in approximately 1% of Galleri tests in people over 50 years of age.
The Galleri test accuracy is measured through Positive Predictive Value and False Positive Rates.
Positive Predictive Value (PPV) is the probability that a person with a “Cancer Signal Detected” test result has cancer.
A False Positive is a test result that indicates that a person has a specific disease or condition when the person actually does not have the disease or condition.
In a recent study, the PPV was 43.1% for study participants with a Cancer Signal Detected result who were diagnosed with cancer. The False Positive Rate was 0.5% for participants without cancer. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.
No, Galleri is not a genetic risk assessment test. A genetic risk assessment is a one time measurement and assesses the future risk of developing cancer. Genetic tests may look at DNA and assess lifelong risk for cancer but cannot detect if a person currently has cancer.
The Galleri test looks for a signal associated with active cancer at the time of your blood draw. Regularly using the Galleri test, alongside recommended cancer screenings, can increase your chance of detecting cancer early.
No, the Galleri test is only commercially available in the US.
Schedule a time and place convenient for you. Visit: Galleri.com/schedule to select either
A partner lab
A trained technician will come to your home, office, or any preferred location to complete your blood draw
Learn more about how your sample is processed at the GRAIL laboratory by watching this video.
Once you receive your sample collection kit, please do not break the quality seal on it. The collection kit should be opened by the trained technician who draws your blood sample.
Store the kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, do not store the collection kit in a car.
To schedule your blood draw visit: Galleri.com/schedule
The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing. Everything needed to complete the blood and return the sample is within the Galleri kit.
If you or your blood draw technician has questions, please call Customer Service: (833) 694‑2553
No, fasting is not required for the Galleri test.
Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes from a vein in your arm.
If you no longer wish to receive your Galleri results, contact GRAIL Customer Service by calling (833) 694‑2553.
Your sample will arrive at the GRAIL lab one to two days after your blood draw. Test results will be available about two weeks after your sample is received at the GRAIL lab.
If you participated in an onsite blood draw sponsored by your employer results may take as long as three weeks.
Your test results can be requested by contacting GRAIL Customer Service by calling (833) 694‑2553.
The Galleri test detected a signal associated with cancer. This result will also include one or two predictions of the tissue type or organ associated with the cancer signal, called “Cancer Signal Origin.”
Results should be interpreted by a healthcare provider. This test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.
False positive and false negative results do occur.
The Galleri test looked for a cancer signal in your blood sample and did not find one. This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Continue with routine cancer screenings your healthcare provider recommends.
A Galleri result of No Cancer Signal Detected does not rule out cancer.
The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early. Using Galleri in addition to recommended single-cancer screenings can increase your chances of detecting cancer early, to allow for earlier treatment.
Galleri does not detect a signal for all cancers and not all cancers can be detected in the blood.
A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.
All results are automatically shared with the provider who ordered the test. When requesting the test, you may provide the information for your primary care provider.
If you would like us to fax your results to an additional healthcare provider, please contact Customer Service by calling (833) 694‑2553 to receive instructions on how to complete a results release form.
By email: customerservice@grail.com
By telephone: (833) 694‑2553
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.
The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.
